Ionetix Corp / DE / Filed SPAC Resale

What the company does

Ionetix Corporation (formerly JDEV Acquisition Corp.) operates through its wholly owned subsidiary Ionetix Radioisotopes, Inc., which was incorporated in Delaware in 2009 to develop smaller, cheaper, lighter and more efficient cyclotrons using superconducting technology for medical and industrial applications. The company's superconducting cyclotron technology enables the design of cyclotrons with a much smaller footprint than conventional cyclotrons and these cyclotrons are cryogen-free, meaning they do not require liquid helium to achieve superconductivity. The company produces hard-to-obtain isotopes using a combination of its proprietary cyclotron technology and third-party-sourced materials and technology. It currently generates revenue in two different medical applications of its technology.

Use of proceeds

The company will not receive any proceeds from the sale of the shares of common stock by the selling stockholders. The selling stockholders may sell the shares from time to time through the means described in the prospectus under 'Plan of Distribution.' The company has borne and will continue to bear the costs relating to the registration of these shares.

Underwriters

The completed effective-prospectus read stated no underwriters.

Extracted from S-1 0001213900-26-086823, filed Aug 7, 2026 and verified against that filing text.

Key risk factors

• No established public trading market

  “There is not currently, and there has never been, any established public trading market for any of our securities.”

• Common stock may not become eligible for trading

  “We cannot assure you that the common stock will become eligible for trading on any exchange or market.”

• Current securities not eligible for trading on exchanges or OTC

  “The common stock is not currently eligible for trading on any national securities exchange, including The Nasdaq Stock Market, LLC, or any over-the-counter markets, including the OTC Markets-OTCQB tier (the “OTCQB”).”

• May not meet initial listing standards

  “We do not currently meet the initial quantitative listing standards of any national securities exchange or over-the-counter trading system, and we can make no assurance that we will be able to meet such initial listing standards.”

• Reliance on third parties

  “our reliance on third parties, including suppliers of specialized radioactive isotopes and other key raw materials, licensing partners, manufacturing and service providers, government entities, independent investigators, research institutions, and strategic partners, and our ability to maintain and expand such relationships”

• Challenges of short half-life isotopes

  “the unique manufacturing, logistics, and operational challenges associated with the short half-life and time-sensitive nature of delivery of radioactive isotopes used in our business”

• Need to raise additional capital

  “our ability to raise additional capital to fund our operations, develop our technology, and maintain sufficient liquidity, and the availability and terms of any such financing”

• Highly regulated emerging markets

  “our pursuit of emerging, highly regulated markets and our ability to commercialize our products and services at scale, including the development of sales, marketing, and distribution capabilities”